In an emulated target trial, a single dose of modified vaccinia Ankara-Bavarian Nordic vaccine was moderately effective in ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.

One dose of modified vaccinia Ankara-Bavarian Nordic vaccine is moderately effective against mpox infection in at-risk communities.

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA Represents the second EMA approval of an MVA-BN-based vaccine for a younger ...

Lessons learned from the COVID pandemic have left the world in a much better position to tackle the current mpox epidemic ...

On September 13, 2024, the World Health Organization (WHO) announced that it added the first vaccine against monkeypox (mpox) to its ...

The African health agency says that Rwanda has started a vaccination campaign against mpox with 1,000 doses it obtained from ...

Mpox vaccines have been administered in Africa for the first time, with several hundred high-risk individuals vaccinated in ...

MVA-BN is approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA. This is the second EMA approval of an MVA-BN-based vaccine for a younger ...

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA Represents the second EMA approval of an MVA-BN-based vaccine for a younger ...

Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to secure 500,000 doses of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) ...